Synergistic activation of lipopolysaccharide-stimulated glial cells by propofol

Biochemical and Biophysical Research Communications

Volumn 438, Issue 2, 2013, Pages 420-426

  Ko, Hyun Myung ^a   Kim, So Yeon ^b   Joo, So Hyun ^a   Cheong, Jae Hoon ^c   Yang, Sung Il ^a   Shin, Chan Young ^a   Koo, Bon Nyeo ^b  

^a Konkuk University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Sahmyook University   (South Korea)

Author keywords

Cytokines; INOS; JNK; Neuronal death; P38

Indexed keywords

ANESTHETIC AGENT; CYTOKINE; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; PROPOFOL; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL CULTURE; CELL DEATH; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLIA CELL; MICROGLIA; NERVE CELL; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUPERNATANT;

CYTOKINES; INOS; JNK; NEURONAL DEATH; P38;

ANESTHETICS, INTRAVENOUS; ANIMALS; ASTROCYTES; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 9; NEUROGLIA; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROPOFOL; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

RATTUS;

EID: 84882622352     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.07.089     Document Type: Article

References (33)

1. Istaphanous G.K., Loepke A.W. General anesthetics and the developing brain. Curr. Opin. Anaesthesiol. 2009, 22:368-373.
2. Adembri C., Venturi L., Pellegrini-Giampietro D.E. Neuroprotective effects of propofol in acute cerebral injury. CNS Drug Rev. 2007, 13:333-351.
3. Roussin A., Montastruc J.L., Lapeyre-Mestre M. Pharmacological and clinical evidences on the potential for abuse and dependence of propofol: a review of the literature. Fundam. Clin. Pharmacol. 2007, 21:459-466.
4. Shibakawa Y.S., Sasaki Y., Goshima Y., Echigo N., Kamiya Y., Kurahashi K., Yamada Y., Andoh T. Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br. J. Anaesth. 2005, 95:803-810.
5. Karwacki Z., Kowianski P., Dziewiatowski J., Domaradzka-Pytel B., Ludkiewicz B., Wojcik S., Narkiewicz O., Morys J. The effect of propofol on astro- and microglial reactivity in the course of experimental intracerebral haemorrhage in rats. Folia. Neuropathol. 2006, 44:50-58.
6. Holownia A., Mroz R.M., Wielgat P., Skiepko A., Sitko E., Jakubow P., Kolodziejczyk A., Braszko J.J. Propofol protects rat astroglial cells against tert-butyl hydroperoxide-induced cytotoxicity; the effect on histone and cAMP-response-element-binding protein (CREB) signalling. J. Physiol. Pharmacol. 2009, 60:63-69.
7. Acquaviva R., Campisi A., Raciti G., Avola R., Barcellona M.L., Vanella L., Li Volti G. Propofol inhibits caspase-3 in astroglial cells: role of heme oxygenase-1. Curr. Neurovasc. Res. 2005, 2:141-148.
8. Peters C.E., Korcok J., Gelb A.W., Wilson J.X. Anesthetic concentrations of propofol protect against oxidative stress in primary astrocyte cultures: comparison with hypothermia. Anesthesiology 2001, 94:313-321.
9. Liu J., Gao X.F., Ni W., Li J.B. Effects of propofol on P2X7 receptors and the secretion of tumor necrosis factor-alpha in cultured astrocytes. Clin. Exp. Med. 2012, 12:31-37.
10. Kim J.W., Lee S.H., Ko H.M., Kwon K.J., Cho K.S., Choi C.S., Park J.H., Kim H.Y., Lee J., Han S.H., Ignarro L.J., Cheong J.H., Kim W.K., Shin C.Y. Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1. Neurochem. Int. 2011, 58:423-433.
11. Shin S.M., Cho K.S., Choi M.S., Lee S.H., Han S.H., Kang Y.S., Kim H.J., Cheong J.H., Shin C.Y., Ko K.H. Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9. Neurochem. Res. 2010, 35:976-985.
12. Kim K.C., Hyun Joo S., Shin C.Y. CPEB1 modulates lipopolysaccharide-mediated iNOS induction in rat primary astrocytes. Biochem. Biophys. Res. Commun. 2011, 409:687-692.
13. Lee W.J., Shin C.Y., Yoo B.K., Ryu J.R., Choi E.Y., Cheong J.H., Ryu J.H., Ko K.H. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 2003, 41:15-24.
14. Shin C.Y., Lee W.J., Choi J.W., Choi M.S., Park G.H., Yoo B.K., Han S.Y., Ryu J.R., Choi E.Y., Ko K.H. Role of p38 MAPK on the down-regulation of matrix metalloproteinase-9 expression in rat astrocytes. Arch. Pharm. Res. 2007, 30:624-633.
15. Smith C., McEwan A.I., Jhaveri R., Wilkinson M., Goodman D., Smith L.R., Canada A.T., Glass P.S. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994, 81:820-828. discussion 826A.
16. Larsen B., Hoff G., Wilhelm W., Buchinger H., Wanner G.A., Bauer M. Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology 1998, 89:1218-1227.
17. Gao J., Zeng B.X., Zhou L.J., Yuan S.Y. Protective effects of early treatment with propofol on endotoxin-induced acute lung injury in rats. Br. J. Anaesth. 2004, 92:277-279.
18. Chen R.M., Wu G.J., Tai Y.T., Sun W.Z., Lin Y.L., Jean W.C., Chen T.L. Propofol reduces nitric oxide biosynthesis in lipopolysaccharide-activated macrophages by downregulating the expression of inducible nitric oxide synthase. Arch. Toxicol. 2003, 77:418-423.
19. Jawan B., Kao Y.H., Goto S., Pan M.C., Lin Y.C., Hsu L.W., Nakano T., Lai C.Y., Sun C.K., Cheng Y.F., Tai M.H., Eng H.L., Wang C.S., Huang C.J., Lin C.R., Chen C.L. Propofol pretreatment attenuates LPS-induced granulocyte-macrophage colony-stimulating factor production in cultured hepatocytes by suppressing MAPK/ERK activity and NF-kappaB translocation. Toxicol. Appl. Pharmacol. 2008, 229:362-373.
20. Wei L., Matsumoto H., Yamaguchi H. Propofol attenuates lipopolysaccharide-induced monocyte chemoattractant protein-1 production through p38 MAPK and SAPK/JNK in alveolar epithelial cells. J. Anesth. 2012.
21. Wu K.C., Yang S.T., Hsia T.C., Yang J.S., Chiou S.M., Lu C.C., Wu R.S., Chung J.G. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells. Anticancer Res. 2012, 32:4833-4842.
22. Kidambi S., Yarmush J., Berdichevsky Y., Kamath S., Fong W., Schianodicola J. Propofol induces MAPK/ERK cascade dependant expression of cFos and Egr-1 in rat hippocampal slices. BMC Res. Notes 2010, 3:201.
23. Fowler C.J. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol. Sci. 2004, 25:59-61.
24. Hauer D., Ratano P., Morena M., Scaccianoce S., Briegel I., Palmery M., Cuomo V., Roozendaal B., Schelling G., Campolongo P. Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology 2011, 114:1380-1388.
25. Guindon J., LoVerme J., Piomelli D., Beaulieu P. The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors. Anesth. Analg. 2007, 104:1563-1569. Table of contents.
26. Patel S., Wohlfeil E.R., Rademacher D.J., Carrier E.J., Perry L.J., Kundu A., Falck J.R., Nithipatikom K., Campbell W.B., Hillard C.J. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br. J. Pharmacol. 2003, 139:1005-1013.
27. Rajesh M., Batkai S., Kechrid M., Mukhopadhyay P., Lee W.S., Horvath B., Holovac E., Cinar R., Liaudet L., Mackie K., Hasko G., Pacher P. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012, 61:716-727.
28. Mukhopadhyay P., Pan H., Rajesh M., Batkai S., Patel V., Harvey-White J., Mukhopadhyay B., Hasko G., Gao B., Mackie K., Pacher P. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 2010, 160:657-668.
29. Oddi S., Latini L., Viscomi M.T., Bisicchia E., Molinari M., Maccarrone M. Distinct regulation of nNOS and iNOS by CB2 receptor in remote delayed neurodegeneration. J. Mol. Med. (Berl) 2012, 90:371-387.
30. Alkaitis M.S., Solorzano C., Landry R.P., Piomelli D., DeLeo J.A., Romero-Sandoval E.A. Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One 2010, 5:e10891.
31. Sheng W.S., Hu S., Ni H.T., Rock R.B., Peterson P.K. WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase. J. Neuroimmune Pharmacol. 2009, 4:244-248.
32. Sheng W.S., Hu S., Min X., Cabral G.A., Lokensgard J.R., Peterson P.K. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005, 49:211-219.
33. Molina-Holgado F., Molina-Holgado E., Guaza C., Rothwell N.J. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 2002, 67:829-836.